These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 29881868)

  • 1. Successful Treatment with Dupilumab in a Patient with Severe, Difficult to Treat Atopic Dermatitis: Beware of Symptomatic Adrenal Insufficiency due to Abrupt Discontinuation of Potent Topical Corticosteroids.
    Ariëns LFM; van der Schaft J; Stades AME; van de Woestijne AA; De Bruin-Weller MS
    Acta Derm Venereol; 2018 Jun; 98(6):601-602. PubMed ID: 29881868
    [No Abstract]   [Full Text] [Related]  

  • 2. Generalized pustular psoriasis (von Zumbusch) following iatrogenic hypocortisolism.
    Augey F; Dissard C; Normand I; Daumont M
    Eur J Dermatol; 2004; 14(6):415-7. PubMed ID: 15564207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.
    Blauvelt A; de Bruin-Weller M; Gooderham M; Cather JC; Weisman J; Pariser D; Simpson EL; Papp KA; Hong HC; Rubel D; Foley P; Prens E; Griffiths CEM; Etoh T; Pinto PH; Pujol RM; Szepietowski JC; Ettler K; Kemény L; Zhu X; Akinlade B; Hultsch T; Mastey V; Gadkari A; Eckert L; Amin N; Graham NMH; Pirozzi G; Stahl N; Yancopoulos GD; Shumel B
    Lancet; 2017 Jun; 389(10086):2287-2303. PubMed ID: 28478972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adrenal insufficiency as a result of long-term misuse of topical corticosteroids.
    Böckle BC; Jara D; Nindl W; Aberer W; Sepp NT
    Dermatology; 2014; 228(4):289-93. PubMed ID: 24751677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low Risk of Adrenal Insufficiency After Use of Low- to Moderate-Potency Topical Corticosteroids for Children With Atopic Dermatitis.
    Davallow Ghajar L; Wood Heickman LK; Conaway M; Rogol AD
    Clin Pediatr (Phila); 2019 Apr; 58(4):406-412. PubMed ID: 30694073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Percutaneous absorption of potent topical corticosteroids in patients with severe atopic dermatitis.
    van Velsen SG; Haeck IM; Bruijnzeel-Koomen CA
    J Am Acad Dermatol; 2010 Nov; 63(5):911-3. PubMed ID: 20950744
    [No Abstract]   [Full Text] [Related]  

  • 7. Dupilumab Improved Alopecia Areata in a Patient with Atopic Dermatitis: A Case Report.
    Uchida H; Kamata M; Watanabe A; Agematsu A; Nagata M; Fukaya S; Hayashi K; Fukuyasu A; Tanaka T; Ishikawa T; Ohnishi T; Tada Y
    Acta Derm Venereol; 2019 Jun; 99(7):675-676. PubMed ID: 30938821
    [No Abstract]   [Full Text] [Related]  

  • 8. Proactive treatment appears to decrease serum immunoglobulin-E levels in patients with severe atopic dermatitis.
    Fukuie T; Nomura I; Horimukai K; Manki A; Masuko I; Futamura M; Narita M; Ohzeki T; Matsumoto K; Saito H; Ohya Y
    Br J Dermatol; 2010 Nov; 163(5):1127-9. PubMed ID: 20545693
    [No Abstract]   [Full Text] [Related]  

  • 9. Dupilumab: A review of its use in the treatment of atopic dermatitis.
    Gooderham MJ; Hong HC; Eshtiaghi P; Papp KA
    J Am Acad Dermatol; 2018 Mar; 78(3 Suppl 1):S28-S36. PubMed ID: 29471919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adrenal insufficiency and growth failure secondary to inhaled corticosteroids: a paradoxical complication.
    Smith A; Doan ML; Roy D; Pinsker JE
    Clin Pediatr (Phila); 2012 Dec; 51(12):1194-6. PubMed ID: 22387925
    [No Abstract]   [Full Text] [Related]  

  • 11. The beginning of biological treatment era in the atopic dermatitis management.
    D'erme AM
    Dermatol Ther; 2016 May; 29(3):208-9. PubMed ID: 26331894
    [No Abstract]   [Full Text] [Related]  

  • 12. Economic Evaluation of Dupilumab for Moderate-to-Severe Atopic Dermatitis: A Cost-Utility Analysis.
    Zimmermann M; Rind D; Chapman R; Kumar V; Kahn S; Carlson J
    J Drugs Dermatol; 2018 Jul; 17(7):750-756. PubMed ID: 30005097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Symptomatic adrenal insufficiency secondary to the use of cutaneous topical steroids for skin-bleaching].
    Sène D; Huong-Boutin DL; Thiollet M; Barete S; Cacoub P; Piette JC
    Rev Med Interne; 2008 Dec; 29(12):1030-3. PubMed ID: 18586357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topical corticosteroids and secondary adrenal insufficiency: a relationship in the shade.
    Márquez Pardo R; Pérez Pelayo M; Aragoneses Calvo A; Gallego Rodriguez S; Martínez Barbeito MB
    Endocrinol Nutr; 2013 Nov; 60(9):e19-20. PubMed ID: 24076040
    [No Abstract]   [Full Text] [Related]  

  • 15. EASI p-EASI: Predicting disease severity in atopic dermatitis patients treated with dupilumab using a combination of serum biomarkers.
    Bakker DS; Ariens LFM; Giovannone B; Hijnen D; Delemarre EM; Knol E; Nierkens S; de Bruin-Weller MS; Thijs JL; Drylewicz J
    Allergy; 2020 Dec; 75(12):3287-3289. PubMed ID: 33305359
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE).
    Simpson EL; Flohr C; Eichenfield LF; Bieber T; Sofen H; Taïeb A; Owen R; Putnam W; Castro M; DeBusk K; Lin CY; Voulgari A; Yen K; Omachi TA
    J Am Acad Dermatol; 2018 May; 78(5):863-871.e11. PubMed ID: 29353026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Adrenal insufficiency and iatrogenic Cushing's syndrome by cutaneous absorption of corticosteroids in an 8 month old infant].
    Dandine M; Lavaud J; Besson-Léaud M; Limal JM
    Ann Dermatol Venereol; 1980 Mar; 107(3):191-5. PubMed ID: 7258980
    [No Abstract]   [Full Text] [Related]  

  • 18. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis.
    Beck LA; Thaçi D; Hamilton JD; Graham NM; Bieber T; Rocklin R; Ming JE; Ren H; Kao R; Simpson E; Ardeleanu M; Weinstein SP; Pirozzi G; Guttman-Yassky E; Suárez-Fariñas M; Hager MD; Stahl N; Yancopoulos GD; Radin AR
    N Engl J Med; 2014 Jul; 371(2):130-9. PubMed ID: 25006719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dupilumab (Dupixent) for moderate to severe atopic dermatitis.
    Med Lett Drugs Ther; 2017 Apr; 59(1519):64-66. PubMed ID: 28419072
    [No Abstract]   [Full Text] [Related]  

  • 20. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial.
    Thaçi D; Simpson EL; Beck LA; Bieber T; Blauvelt A; Papp K; Soong W; Worm M; Szepietowski JC; Sofen H; Kawashima M; Wu R; Weinstein SP; Graham NM; Pirozzi G; Teper A; Sutherland ER; Mastey V; Stahl N; Yancopoulos GD; Ardeleanu M
    Lancet; 2016 Jan; 387(10013):40-52. PubMed ID: 26454361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.